Investors

investors

Syncromune™ is well-positioned to develop a scalable platform for long-term, sustained growth. Our innovative technology provides the potential to treat numerous types of metastatic solid tumor cancers. 

CORPORATE OVERVIEW

Syncromune™ is a privately held, clinical stage biopharmaceutical company dedicated to the development of better immunotherapies for metastatic solid tumor cancers.  We are at the forefront of developing combination immunotherapies, which several thought leaders consider to be the future of cancer therapy. We are committed to bringing life-changing treatments to patients with unmet medical needs by fighting cancer in a new way. 

The company is currently developing Syncrovax™, a proprietary platform technology that uses a combination approach to synchronize the timing and location of tumor neoantigen release with the functional activation and education of immune cells. An in situ vaccine is created from the patient’s own tumor antigens, making it a personalized treatment for each patient. The platform is designed to educate T cells to induce a systemic anti-tumor response at the site of the treated tumor as well as metastases throughout the body.

PRESS RELEASES

UPCOMING EVENTS

DEC 6

December 6th – 7th, 2022

Miami, FL

Meeting Information

Request a Meeting with Syncromune

DEC 13

December 13th – 16th, 2022

Fort Lauderdale, FL

Meeting Information

Request a Meeting with Syncromune

PAST EVENTS

NOV 2

November 2nd – 4th, 2022

Miami, FL
Hyatt Regency Miami

Meeting Information

Request a Meeting with Syncromune

NOV 8

37th Annual Meeting

November 8th – 12th, 2022

Boston, MA

Meeting Information

Request a Meeting with Syncromune

COMPANY PRESENTATIONS

Contact Information

Danielle Hobbs

EVP, Investor Relations & Corporate Communications

Social Media

Disclaimer

The information contained in our press releases and presentations should be considered accurate only as of the date it was originally issued. Syncromune™ disavows any obligation to update the information contained in these press releases and presentations after the date of their issuance.